Landsteiner Genmed Obtains 2,055M € of Non-Dilutive Funding from Next Generation EU Funds to Develop New Anticancer Immunomodulatory Agents
Landsteiner Genmed has announced that it has obtained 2,055M € of non-dilutive funding from Next Generation EU Funds to study the anticancer effects of new molecules with immunomodulatory properties.